Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Brand names: Praluent
12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (LDL) receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.
Contraindications
8 documented side effects by frequency
8 Reddit threads analysed for ALIROCUMAB
Overall Sentiment
Mixed
Comparison Threads
5
Avg Post Score
5 upvotes
Most discussed side effects in community
Threads directly comparing ALIROCUMAB to other medications
#111 Clinical Trials updated on 2021-07-28 All 111 studies in this list are **actively recruiting** at one or more locations. Most studies in this list **accept healthy volunteers** with the exception of any studies missing a 'Y' in the Healthy Volunteers column. Those studies may or may not be ac
#102 Clinical Trials updated on 2021-07-27 All 102 studies in this list are **actively recruiting** at one or more locations. Most studies in this list **accept healthy volunteers** with the exception of any studies missing a 'Y' in the Healthy Volunteers column. Those studies may or may not be ac
#54 Clinical Trials updated on 2021-07-19 All 54 studies in this list are **actively recruiting** at one or more locations. Most studies in this list **accept healthy volunteers** with the exception of any studies missing a 'Y' in the Healthy Volunteers column. Those studies may or may not be acce
#136 Clinical Trials updated on 2021-07-23 All 136 studies in this list are **actively recruiting** at one or more locations. Most studies in this list **accept healthy volunteers** with the exception of any studies missing a 'Y' in the Healthy Volunteers column. Those studies may or may not be ac
#74 Clinical Trials updated on 2021-07-22 All 74 studies in this list are **actively recruiting** at one or more locations. Most studies in this list **accept healthy volunteers** with the exception of any studies missing a 'Y' in the Healthy Volunteers column. Those studies may or may not be acce
Here are the links to the two abstracts in NEJM: [Alirocumab abstract](http://www.nejm.org/doi/full/10.1056/NEJMoa1501031) [Evolocumab abstract](http://www.nejm.org/doi/full/10.1056/NEJMoa1500858) I saw the evolocumab story on NBC Nightly News last night, and you know if I saw it, thousands upon tho
Does anyone know of any studied benefit in switching between evolocumab and alirocumab? If you’ve heard of/read any articles, please point me in that direction as well. TIA
# Enlicitid: Erster oraler PCSK9-Inhibitor – Game-Changer für Cholesterin-Therapie? Auf der AHA-Jahrestagung in New Orleans wurden gerade die Phase-3-Daten zu **Enlicitid (Enlicitide Decanoate, MK-0616)** von Merck/MSD vorgestellt. Falls ihr es nicht mitbekommen habt: Das könnte ein ziemlicher Durch
Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.
10 available comparisons
Dosage Forms
Tablet
Route
Subcutaneous